Total Payments
$50,495
2024 Payments
$32,842
Companies
30
Transactions
123
Medicare Patients
343
Medicare Billing
$19,525
Payment Breakdown by Category
Research$48,656 (96.4%)
Food & Beverage$1,829 (3.6%)
Education$10.52 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $48,656 | 13 | 96.4% |
| Food and Beverage | $1,829 | 109 | 3.6% |
| Education | $10.52 | 1 | 0.0% |
Payments by Type
Research
$48,656
13 transactions
General
$1,839
110 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $42,656 | 12 | $0 (2024) |
| Becton, Dickinson and Company | $6,000 | 1 | $0 (2022) |
| PFIZER INC. | $323.79 | 16 | $0 (2022) |
| Novo Nordisk Inc | $238.75 | 15 | $0 (2021) |
| Lilly USA, LLC | $194.59 | 12 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $163.67 | 4 | $0 (2022) |
| AbbVie Inc. | $108.59 | 7 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $107.51 | 8 | $0 (2019) |
| GlaxoSmithKline, LLC. | $101.90 | 7 | $0 (2024) |
| Shire North American Group Inc | $100.94 | 8 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,842 | 4 | Eli Lilly and Company ($32,827) |
| 2023 | $2,248 | 15 | Eli Lilly and Company ($2,060) |
| 2022 | $7,098 | 16 | Becton, Dickinson and Company ($6,000) |
| 2021 | $338.22 | 11 | Eli Lilly and Company ($149.66) |
| 2020 | $6,774 | 4 | Eli Lilly and Company ($6,745) |
| 2019 | $94.48 | 7 | Novo Nordisk Inc ($44.35) |
| 2018 | $441.41 | 33 | AstraZeneca Pharmaceuticals LP ($79.71) |
| 2017 | $659.96 | 33 | PFIZER INC. ($182.87) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $23,026.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $9,702.00 | Research |
| Study: A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | ||||||
| 08/26/2024 | Eli Lilly and Company | — | — | In-kind items and services | $99.20 | Research |
| Study: A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | ||||||
| 01/03/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: RESPIRATORY | ||||||
| 10/31/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: VACCINES | ||||||
| 10/05/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Diabetes | ||||||
| 09/19/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: VACCINES | ||||||
| 07/24/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Diabetes | ||||||
| 06/02/2023 | Seqirus USA Inc | Fluad Quadrivalent (Biological), FLUCELVAX QUADRIVALENT | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Vaccines | ||||||
| 05/22/2023 | Eli Lilly and Company | — | — | In-kind items and services | $795.01 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | ||||||
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $555.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 04/06/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Diabetes | ||||||
| 03/02/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Diabetes | ||||||
| 02/09/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: NEUROSCIENCE | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $361.30 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $348.34 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 01/14/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: ANTIBIOTIC | ||||||
| 11/30/2022 | Becton, Dickinson and Company | BD Veritor InfoScan Module (Device) | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: COVID-19 • Category: Diagnostic Systems | ||||||
| 11/01/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.95 | General |
| Category: NEUROSCIENCE | ||||||
| 10/07/2022 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: Diabetes | ||||||
| 09/29/2022 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 09/24/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: PRIMARY CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | Eli Lilly and Company | $23,821 | 2 |
| A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | Eli Lilly and Company | $9,702 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $7,173 | 3 |
| COVID-19 | Becton, Dickinson and Company | $6,000 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $596.66 | 2 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $555.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $361.30 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $348.34 | 1 |
| A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | Eli Lilly and Company | $99.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 107 | 382 | $8,521 | $3,432 |
| 2022 | 7 | 128 | 317 | $11,248 | $6,803 |
| 2021 | 2 | 24 | 26 | $2,996 | $1,893 |
| 2020 | 4 | 84 | 176 | $13,994 | $7,397 |
Total Patients
343
Total Services
901
Medicare Billing
$19,525
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 23 | $3,542 | $1,789 | 50.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 27 | $3,267 | $1,356 | 41.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 28 | $1,232 | $248.10 | 20.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 22 | 260 | $260.00 | $21.42 | 8.2% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 11 | 44 | $220.00 | $16.75 | 7.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 38 | $5,852 | $3,783 | 64.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $1,573 | $922.01 | 58.6% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 16 | 16 | $1,120 | $811.71 | 72.5% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 20 | 40 | $1,320 | $650.44 | 49.3% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 13 | 13 | $455.00 | $445.90 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 16 | 17 | $748.00 | $173.31 | 23.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 13 | 180 | $180.00 | $16.43 | 9.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 13 | 14 | $2,156 | $1,278 | 59.3% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 11 | 12 | $840.00 | $615.72 | 73.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2020 | 25 | 66 | $4,620 | $2,969 | 64.3% |
| 99490 | Chronic care management services at least 20 minutes per calendar month | Office | 2020 | 29 | 66 | $4,950 | $2,123 | 42.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 16 | $2,464 | $1,215 | 49.3% |
| 99457 | Remote physiologic monitoring treatment management services, health care professional time in a calendar month requiring interactive communication with the patient/caregiver; first 20 minutes | Office | 2020 | 14 | 28 | $1,960 | $1,090 | 55.6% |
About Dr. Michael Vaughn, M.D
Dr. Michael Vaughn, M.D is a Family Medicine healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730249525.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Vaughn, M.D has received a total of $50,495 in payments from pharmaceutical and medical device companies, with $32,842 received in 2024. These payments were reported across 123 transactions from 30 companies. The most common payment nature is "" ($48,656).
As a Medicare-enrolled provider, Vaughn has provided services to 343 Medicare beneficiaries, totaling 901 services with total Medicare billing of $19,525. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Birmingham, AL
- Active Since 12/11/2006
- Last Updated 09/30/2010
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1730249525
Products in Payments
- BD Veritor InfoScan Module (Device) $6,000
- JARDIANCE (Drug) $216.27
- TRULICITY (Drug) $114.95
- VRAYLAR (Drug) $112.91
- EUCRISA (Drug) $97.08
- Saxenda (Drug) $86.21
- Adzenys XR-ODT (Drug) $80.93
- BYDUREON (Drug) $79.71
- SHINGRIX (Biological) $71.69
- VYVANSE (Drug) $62.38
- LYRICA (Drug) $61.67
- PREVNAR 20 (Biological) $56.81
- Victoza (Drug) $52.73
- PREVNAR - 13 (Biological) $47.12
- Tresiba (Drug) $43.86
- NURTEC ODT (Drug) $41.04
- Ozempic (Drug) $38.81
- MYDAYIS (Drug) $38.56
- CHANTIX (Drug) $34.65
- Evekeo (Drug) $33.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Birmingham
Dr. Lashelle Barmore, D.o, D.O
Family Medicine — Payments: $484,700
Family Medicine $484,700
Dr. Nova Law, M.d, M.D
Family Medicine — Payments: $162,847
Family Medicine $162,847
Dr. Christopher Carter, M.d, M.D
Family Medicine — Payments: $42,656
Family Medicine $42,656
Dr. Terry Smith, M.d, M.D
Family Medicine — Payments: $23,057
Family Medicine $23,057
Scott Weisberg, M.d, M.D
Family Medicine — Payments: $18,210
Family Medicine $18,210
Kennedy Kunz, Md, MD
Family Medicine — Payments: $14,191
Family Medicine $14,191